These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11762353)

  • 1. Nuclear medicine imaging of neuroendocrine tumours.
    Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
    Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?].
    Bombardieri E; Maccauro M; Castellani MR; Chiti A; Procopio G; Bajetta E; Seregni E
    Minerva Endocrinol; 2001 Dec; 26(4):197-213. PubMed ID: 11782705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
    Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
    Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
    Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of PET in localization of neuroendocrine and adrenocortical tumors.
    Eriksson B; Bergström M; Sundin A; Juhlin C; Orlefors H; Oberg K; Långström B
    Ann N Y Acad Sci; 2002 Sep; 970():159-69. PubMed ID: 12381551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.
    Eriksson B; Bergström M; Orlefors H; Sundin A; Oberg K; Långström B
    Q J Nucl Med; 2000 Mar; 44(1):68-76. PubMed ID: 10932603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
    Shapiro B
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
    Kaltsas GA; Mukherjee JJ; Grossman AB
    Ann Oncol; 2001; 12 Suppl 2():S47-50. PubMed ID: 11762352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
    Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
    Oberg K; Eriksson B
    Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
    Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
    Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
    Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
    Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.
    Hoefnagel CA
    Eur J Nucl Med; 1994 Jun; 21(6):561-81. PubMed ID: 7915987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Other PET tracers for neuroendocrine tumors.
    Koopmans KP; Glaudemans AW
    PET Clin; 2014 Jan; 9(1):57-62. PubMed ID: 25029934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
    Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
    Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
    J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
    Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.